Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
781 to 800 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Full genome characterization of a human-porcine reassortment G12P[7] rotavirus and its pathogenicity in piglets. | Transbound Emerg Dis | 2022 | 36150417 | PubTator, text mining | PubMed |
| SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion. | Viruses | 2022 | 36146796 | PubTator, text mining | PubMed |
| Cellular Lipids-Hijacked Victims of Viruses. | Viruses | 2022 | 36146703 | PubTator, text mining | PubMed |
| Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival. | Viruses | 2022 | 36146700 | PubTator, text mining | PubMed |
| Identification of MHC-I-Presented Porcine Respiratory and Reproductive Syndrome Virus (PRRSV) Peptides Reveals Immunogenic Epitopes within Several Non-Structural Proteins Recognized by CD8+ T Cells. | Viruses | 2022 | 36146698 | PubTator, text mining | PubMed |
| Immune Evasion of SARS-CoV-2 Omicron Subvariants. | Vaccines (Basel) | 2022 | 36146623 | PubTator, text mining | PubMed |
| Pharmacological Potential of Flavonoids against Neurotropic Viruses. | Pharmaceuticals (Basel) | 2022 | 36145370 | PubTator, text mining | PubMed |
| Synthesis of Novel N4-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents. | Pharmaceuticals (Basel) | 2022 | 36145365 | PubTator, text mining | PubMed |
| In Silico Study towards Repositioning of FDA-Approved Drug Candidates for Anticoronaviral Therapy: Molecular Docking, Molecular Dynamics and Binding Free Energy Calculations. | Molecules | 2022 | 36144718 | PubTator, text mining | PubMed |
| Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach. | Int J Mol Sci | 2022 | 36142620 | PubTator, text mining | PubMed |
| Proteomic Analysis Identifies Molecular Players and Biological Processes Specific to SARS-CoV-2 Exposure in Endothelial Cells. | Int J Mol Sci | 2022 | 36142365 | PubTator, text mining | PubMed |
| SARS-CoV-2 Variability in Patients and Wastewaters-Potential Immuno-Modulation during the Shift from Delta to Omicron. | Biomedicines | 2022 | 36140181 | PubTator, text mining | PubMed |
| A computational study of metal-organic frameworks (MOFs) as potential nanostructures to combat SARS-CoV-2. | Sci Rep | 2022 | 36127369 | PubTator, text mining | PubMed |
| A Preliminary Genomic Analysis of the Omicron Variants of SARS-CoV-2 in Central India During the third wave of the COVID-19 Pandemic. | Arch Med Res | 2022 | 36123226 | PubTator, text mining | PubMed |
| Prevalence and Genetic Characteristics of Japanese Encephalitis Virus among Mosquitoes and Pigs in Hunan Province, China from 2019 to 2021. | J Microbiol Biotechnol | 2022 | 36116917 | PubTator, text mining | PubMed |
| Autoprocessing and oxyanion loop reorganization upon GC373 and nirmatrelvir binding of monomeric SARS-CoV-2 main protease catalytic domain. | Commun Biol | 2022 | 36114420 | PubTator, text mining | PubMed |
| Computational exploration of the dual role of the phytochemical fortunellin: Antiviral activities against SARS-CoV-2 and immunomodulatory abilities against the host. | Comput Biol Med | 2022 | 36103744 | PubTator, text mining | PubMed |
| Bisubstrate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase. | ACS Med Chem Lett | 2022 | 36097498 | PubTator, text mining | PubMed |
| Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults. | Antimicrob Agents Chemother | 2022 | 36094202 | PubTator, text mining | PubMed |
| Evasion of interferon-mediated immune response by arteriviruses. | Front Immunol | 2022 | 36091073 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=40